Mesenchymal stem cells in lung diseases and their potential use in COVID-19 ARDS: A systematized review

Armstrong, Bruna Benigna Sales; Pedroso, Juan Carlos Montano; Carvalho Jr., José da Conceição; Ferreira, Lydia Masako

doi:10.1016/j.clinsp.2023.100237

Brasil

home Sumário navigate_before Anterior Atual Seguinte navigate_next

home Sumário

Review articles • Clinics 78 • 2023 • https://doi.org/10.1016/j.clinsp.2023.100237 linkcopy

Mesenchymal stem cells in lung diseases and their potential use in COVID-19 ARDS: A systematized review

Authorship SCIMAGO INSTITUTIONS RANKINGS

Highlights

None of the analized studies related serious adverse effects or toxicity to IV ASCs administration.
This review suggests optimism in IV ASCs for lung damage in severe COVID-19 ARDS.
Further studies on IV ASCs in COVID-19 are needed for standard dosage.

Abstract

COVID-19 can converge with the pro-inflammatory immunoregulatory mechanisms of chronic lung diseases. Given the disorders inherent to lung transplantation and the inexistence of other definitive therapeutic alternatives, Adipose tissue-derived Stem Cells (ASCs) presented themselves as a therapeutic hope. The purpose of this review is to assess the basis for the potential use of ASCs in lung diseases unresponsive to conventional therapy, relating to their possible use in COVID-19 ARDS. 35 studies comprised this review, 14 being narrative reviews, 19 preclinical trials and two proofs of concept. COVID-19 can converge with the pro-inflammatory immunoregulatory mechanisms of chronic lung diseases. In view of the disorders inherent to lung transplantation and the inexistence of definitive therapeutic alternatives, Adipose tissue-derived Stem Cells (ASCs) presented themselves as a therapeutic hope. Its detailed reading indicated the absence of serious adverse effects and toxicity to the administration of ASCs and suggested possible effectiveness in reducing lung damage, in addition to promoting the recovery of leukocytes and lymphocytes with its immunomodulatory and anti-apoptotic effects. The revised clinical data suggests optimism in the applicability of ASCs in other immunoinflammatory diseases and in severe COVID-19 ARDS. However, further studies are needed to develop a consensus on the methods of collection of ASCs, the ideal dosage schedule, the most effective time and route of administration, as well as on the definition of indications for the administration of ASCs in cases of COVID-19 for conducting clinical trials in near future.

Keywords Mesenchymal stem cells; COVID-19; Lung disease

Authors	Pathology	Effectiveness analysis				Safety analysis
Authors	Pathology	Study method	Participants	Intervention	Results observed	Serious adverse events	Light adverse events
Barczyk et al. 2015	IPF	• Narrative review	Mices	• Tzouvelekis: autologous	Cell therapy for IPF appears to be overestimated based on currently available information.	None on IV infusion of ASCs. Tzouvelekis: Worsening of dyspnea: n= 2 (14%).	Transient fever tzouvelekis:
		• Narrative review		• Lee: xerogenic			Fever: n= 7 (50%).
		• NR number of tests used in its preparation (16 in the table in the article exclusively about 1 of the 5 models of pulmonary fibrosis induction and 2 clinical tests in humans/ presented 159 references in all)		• Administration IV and EB		Oxygen desaturation: n= 2 (14%).	Cough worsening; n= 2 (14%).
				• Tzouvelekis: 0.5 × 10⁶/Kg, 3 doses with monthly intervals
		• NR number of articles with ASCs (2 present in the table on pulmonary fibrosis induced by BLM and also presents 4 references that directly cite ASCS)		• Lee: 4 doses of 1 × 10⁶ applied concurrently with BLM
		• Analysis of histopathology, biochemistry and immunohistochemistry
		• Stem cell markers: (+) CD44, CD29, CD105 and CD90 and (-) CD45 and CD34
Srour e Thébaud 2015	BLM-induced pulmonary fibrosis (PF)	• Narrative review	Mices	• Culture-expanded human adipose-derived xerogenic MSCs	MSC therapy was effective in animal models of BLM-induced lung injury. Most studies examined the early inflammatory phase providing a better representation of acute disease exacerbations.	None	Transient Fever
		• 17 studies used in its preparation		• Culture-expanded human adipose-derived xerogenic MSCs
		• 2 articles with ASCs (but only one IV)		• Dose: 0.3 × 10⁶ cells/kg IV (4 doses in weeks 8, 10, 12, and 14)
		• Analysis of histopathology, collagen deposition, mortality, Aschcrott score and inflammatory markers: TGF-b, TNF-α, IFN-γ, IL6, IL1, MMP2, MMP9, MMP13
		• The review does not describe the stem cell markers of the reviewed studies (CD)
Stabler et al. 2015	Chronic lung diseases (ARDS, asthma and exposure to cigarette smoke)	• Narrative review	Guinea pigs and felines; ARDS patients	• Culture-expanded adipose-derived allogeneic MSCs	MSC-based therapies were effective and phase 1 clinical trials proved the safety of MSC therapy in ARDS, asthma, and exposure to cigarette smoke.	None	None
		• 20 studies used in its preparation		• Culture-expanded adipose-derived allogeneic MSCs
		• 3 articles with ASCs (3 pre-clinical and 1 clinical)		• Zheng: 1 × 10⁶ cell/kg IV (DU)
		• Analysis of the ability to differentiate clinical effects, anti-inflammatory effects and safety		• Preclinical: NR dosage
		• The review does not describe the stem cell markers of the reviewed studies (CD)		• Preclinical: NR dosage
Geiger et al. 2017a	FPI; Acute respiratory distress syndrome, Chronic obstructive pulmonary disease	• Narrative review	NR	• Allogeneic and autologous MSCs derived from adipose tissue, expanded by culture	MSC-based therapies for pulmonary diseases present themselves as potential viable treatment options for clinical application. In particular, the potential of genetically modified MSCs, which allows for a considerable increase in therapeutic activity.	NR (Not reported)	NR
		• 24 tests (clinical and pre-clinical)
		• 3 tests with ASCs (2 clinical and 1 pre-clinical)
		• Analysis of lung function and safety		• Administered intravenously and EB
		• The review does not describe the stem cell markers of the reviewed studies (CD)		• Phase I: 1 × 10⁶ cell/kg
				• Phase Ib: 5 × 10⁵ MSC·kg-1
				• Pre-clinical: 40 × 10⁶ MSCs·kg-1
				• NR number of doses
Antoniou et al. 2018	FPI; ARDS, COPD, severe emphysema, advanced pulmonary sarcoidosis	• Narrative review	Patients with ARDS	• Adipose tissue-derived, culture-expanded allogeneic MSCs	Recent clinical studies of the administration of autologous or allogeneic MSCs in patients with various lung diseases provide adequate evidence for the safety of using MSCs in these patient groups	NR (Not reported)	None
		• 8 clinical tests
		• 2 tests with ASCs
		• Analysis of pulmonary inflammation markers in IV administration		• Administered via IV and EB
				• Single dose of 1 × 10⁶ cell./kg
		• The review does not describe the stem cell markers of the reviewed studies (CD)		• Single dose of 1 × 10⁶ cell./kg
Harrell et al. 2019	Immunoinflammatory lung diseases (ARDS, pneumonia, asthma, COPD, IPF)	• Narrative review	NR	• MSCs (does not say whether autologous or allogeneic) derived from adipose tissue, placenta, umbilical cord and culture-expanded bone marrow	The reviewed clinical trials suggest that the administration of MSCs was well tolerated and that MSC-based therapy is a safe therapeutic approach, as only a limited number of side effects have been reported.	None	Bronchitis and common cold were the most frequent
		• NR number of studies used in its preparation, but presented 119 references
		• 4 articles with ASCs (1 clinician and 1 preclinical)
		• Analysis of markers of lung inflammation, improvement in quality of life, lung function and safety		• Zheng: 1 × 10⁶ cell./kg IV (DU)
				• Other ASCs: NR
		• The review does not describe the stem cell markers of the reviewed studies (CD)		• Other ASCs: NR
Zanoni et al. 2019	Radiation-induced lung injury (LP)	• Narrative review	Humans and Mices	• NR origin (auto, alo, xero) of adipose stem cells	The lack of standardized methods for collecting MSCs and little or no information available on optimal dosage, timing and route of administration make it difficult to imagine the use of MSC-based therapy in clinical practice in the near future.	NR (Not reported)	NR
		• NR total number of studies used in its preparation (has 203 references)		• NR origin (auto, alo, xero) of adipose stem cells
		• NR number of articles with ASCs (12 references cite ASCS directly)		• Administration IV and EB
		• Analysis of histopathology, biochemistry and immunohistochemistry		• NR dose
		• Stem cell markers: (+): CD105 (endoglin, SH2), CD73 (ecto-50-nucleotidase) and CD90 (Thy1) \| (-): CD45, CD19 or CD79, CD14 or CD11b, and HLA-DR....		• NR dose
Behnke et al. 2020	Bronchopulmonary dysplasia, Asthma, acute lung injuries (systemic and infectious), Chronic obstructive pulmonary disease (COPD)	• Narrative review	Humans and Mices	ORIGIN ADIPOSE STEM CELL PRE CLINICOS: • Cigarette smoke: (human × rat, human) • Elastase: mouse • Asthma: human • ALI: Humans • COPD: human • BLM: mices	The preclinical results raise high hopes that MSC-based therapies will successfully lead to cures rather than just relief of disease symptoms. Available data from clinical trials have proven the safety of such an age- and disease-entity approach.	In preclinical reports, there was death from DIC and cardiac and respiratory dysfunction due to the infusion of high doses of MSCs.	None
		• 75 studies used in its preparation
		• 12 articles with ASCs [only 8 IVs: 1 from asthma, 1 from ALI, 1 from COPD, 3 from BLM, 2 from cigarette smoke (1 of them smoke or elastase) and 1 elastase (compare IV with IT)]
		• Analysis of histopathology, biochemistry and immunohistochemistry		PRECLINICAL DOSE: • Cigarette smoke: 1 study used 3 × 10⁵ in 4 doses (weeks 8, 10, 12 and 14) and the other used 1 × 10⁵ DU • Elastase: 1 × 10⁵ DU • Asthma: 1 × 10⁵ DU • ALI: 1 × 10⁶ DU • COPD: 1 × 10⁶ DU • BLM: 2 studies used 5 × 10⁵ DU / and 1 study used 4 × 107 in 3 doses (days 3, 6 and 9)
		• The review does not describe the stem cell markers of the reviewed studies (CD)
				CLINIC • NR dose, neither if it was autologous or allogeneic.
Cruz e Rocco 2020b	Chronic lung diseases (Asthma, COPD, Idiopathic pulmonary fibrosis-IPF, PAH, silicosis)	• Narrative review	Humans and Mices	• NR origin (auto, alo, xero) of adipose stem cells	MSC-based therapy is a promising alternative for the treatment of chronic lung diseases. Preclinical studies with MSCs generated great enthusiasm for their therapeutic potential in these conditions. Early clinical trials demonstrated that MSC administration is safe, with few adverse effects	None	None
		• NR total number of studies used in its preparation (it has 99 references)		• NR origin (auto, alo, xero) of adipose stem cells
		• NR number of articles with ASCs (10 references cite ASCS directly)		• Administration IV
		• Analysis of histopathology, biochemistry and immunohistochemistry		• NR dose
		• Stem cell markers: (+) CD105, CD73, and CD90 and (-) CD45, CD34, CD14 or CD11b, CD79 alpha, or CD19, and HLA-DR....		• NR dose
Ntolios et al. 2020	IPF	• Narrative review	Patients with mild to moderate IPF	• Allogeneic MSCs derived from adipose tissue, placenta and culture-expanded bone marrow	Clinical trials currently completed suggest that cell therapies are safe and can be effective	None	Phase Ib EB: minor adverse effects, mainly related to bronchoscopy.
		• 9 clinical tests
		• 3 tests with ASCs (12, 15, 60 pcts)
		• Clinical and radiological analysis
		• Safety and laboratory analysis of inflammatory markers: C-reactive protein, LDH, d-dimer and ferritin		• Administered intravenously and endobronchial
		• Stem cell markers (+): CD105, CD73, CD90, CD44, CD71, Stro1, CD106 (VCAM-1), CD166 (ALCAM), ICAM-1, CD29; and (-): CD45, CD34, CD11, CD80, CD86, CD40, CD31 (PECAM-1), CD18, CD56, HLA II		• Administered intravenously and endobronchial
				• 1 Phase I: 1 × 10⁶ cells/kg IV (DU)
				• 2 Phase Ib: 5 × 10⁵ cell./kg EB (3 doses 1 month apart)
Qin e Zhao 2020	ARDS and COVID-19	• Narrative review	NR	• MSCs (does not say whether autologous or allogeneic) derived from adipose tissue, placenta and culture-expanded bone marrow	The safety of MSC therapy has been demonstrated in early-stage clinical trials with a small number of patients. Systemic administration of MSC proved to be effective.	None	None
		• 18 tests (clinical and pre-clinical)
		• 2 tests with ASCs (1 clinician and 1 preclinical)
		• Analysis of markers of lung inflammation, onset of antimicrobial response, protective effects, decrease in damage to distal organs		• Clinical: 1 × 10⁶ cells/kg IV (DU)
				• Pre-clinical: NR
		• The review does not describe the stem cell markers of the reviewed studies (CD)		• Pre-clinical: NR
Rogers et al. 2020a	ARDS and COVID-19	• Narrative review	Mices and humans	• NR reported dose	Cell-based therapies have demonstrated safety in human clinical trials, warranting further investigation	None	Transient Fever
		• NR total number of studies used in its preparation		REFERRED DOSE:
		• NR number of articles with ASCs		• Perlee: 4 × 10⁶ ASCs/kg (NR number of doses)
		• Analysis of histopathology, biochemistry and immunohistochemistry		• Zheng: 1 × 10⁶ DU
		• The review does not describe the stem cell markers of the reviewed studies (CD)		• Zheng: 1 × 10⁶ DU
Yen et al. 2020b	Immunoinflammatory lung diseases (ARDS, COPD, IPF…)	• Narrative review	NR	• Allogeneic and autologous MSCs derived from adipose tissue, expanded by culture	MSC for COVID-19 should be targeted to very severe cases where ARDS and an exuberant immune response are observed. Preclinical MSC data were quite consistent, and MSC clinical data in other immunoinflammatory diseases support the relative safety of MSC therapy, even though the efficacy may be more difficult to interpret.	NR (Not reported)	NR
		• 68 clinical trials
		• 12 tests with ASCs
		• Does not report the analysis parameters of the results
		• The review does not describe the stem cell markers of the reviewed studies (CD)		• Does not report via Administration
				• Does not report dose schedule
Xiao et al. 2020	ARDS and COVID-19	• Narrative review	Patients with ARDS	• MSCs (does not say whether autologous or allogeneic) derived from adipose tissue, menstrual blood, umbilical cord and culture-expanded bone marrow	Safety and possible efficacy have been demonstrated in some patients with ARDS. Although some progress has been made, there is insufficient clinical evidence to prove the efficacy of MSCs in treating ARDS.	None	None
		• NR number of studies used in its preparation, but presented 48 references
		• 1 articles with ASCs (clinical)
		• Analysis of markers of lung inflammation, clinical improvement and safety
				• Zheng: 1 × 10⁶ cell/kg IV (DU)
		• The review does not describe the stem cell markers of the reviewed studies (CD)		• Zheng: 1 × 10⁶ cell/kg IV (DU)

Authors	Pathology	Effectiveness analysis					Safety analysis
Authors	Pathology	Study method	Participants	Intervention	Follow-up	Results observed	Serious adverse events	Light adverse events
Schweitzer et al. (2011)	Cigarette smoke-induced lung injury (LP)	• Pre-clinical	• Mices	• Allogeneic MSCs derived from adipose tissue of animal and xerogenic (human) origin, expanded by culture	• Follow up of lung tissue: 1, 7, and 21 days after administration	The results suggest a useful therapeutic effect of adipose stem cells in both lungs and systemic injury induced by cigarette smoke and imply a pulmonary vascular protective function of paracrine factors derived from adipose stem cells.	NR (Not reported)	NR
		• 20 mices
		• NR randomization of group division
		• Biochemical and immunohistochemical analysis
		• Biochemical and immunohistochemical analysis		• Administration IV
		• Inflammatory markers: caspase 3, via MAPK		• Single dose: 3 × 10⁵ cells ASCs (in both experiments)
		• Stem cell markers: anti-CD31b		• Single dose: 3 × 10⁵ cells ASCs (in both experiments)
Gao et al. (2013)	Acute Lung Injury (ALI)	• Pre-clinical	• Mices	• Xerogenic MSCs derived from human adipose tissue, expanded by culture	• Follow up: The culture medium was collected at 24 h, 48 h and 72 h; rat plasma was collected in 7 days.	ASCs were able to attenuate the severity of ALI and pulmonary edema.	NR (Not reported)	NR
		• 25 Mices
		• RCT - control group (10)
		• Clinical, biochemical, immunohistochemical and wet-dry lung ratio analysis		• Administration IV
				• Single dose MSC: ∼5 × 10⁵ ASC
		• Inflammatory marker: NO
		• Stem cell markers: PE-CD34, FITC CD90 and PE-106 antibodies
Cho et al. (2014)	Asthma	• Pre-clinical	• Mices	• Allogeneic MSCs derived from adipose tissue of animal origin, expanded by culture	• Follow up: airway hyperresponsiveness was assessed on day 23. The frequency of sneezing and nasal rubbing that occurred within 10 min of the last ovalbumin administration (day 23). The mices were euthanized on day 24. At least 48 h after the last OVA administration, serum was collected from the mices.	IV ASCs significantly reduced allergic symptoms and inhibited eosinophilic inflammation.	NR (Not reported)	NR
		• 20 mices
		• NR randomization of group division
		• Clinical, biochemical, immunohistochemical and histopathological analysis		• Administration IV
				• 4 Doses: 1 × 10⁷/mL ASC cells suspended in PBS (days 12, 13, 19 and 20)
		• Inflammatory markers: IL-4, IL-5, IL-10, IL-13, IFN-γ, TGF-β, Ig E, IgG1, and IgG2a, PGE2, IDO enzyme
		• Stem cell markers: (+): Sca1, CD44, CD90; (-): CD45, CD 117 and CD11b
Feizpour et al. (2014)	COPD	• Pre-clinical	• Guinea pigs	• Allogeneic cryopreserved MSCs derived from adipose tissue of animal origin, expanded by culture	• Follow-up: 14 days	No significant changes were observed in the group that received ASCs IV.	NR (Not reported)	NR
		• 36 guinea pigs
		• RCT- control group (6 via IT and 5 via IV)
		• Tracheal, biochemical and cytological responsiveness analysis		• Administration IV and IT
		• Inflammatory markers: IL-8		• Single dose: 0.3 mL PBS containing 10⁶ ASCs (both lanes)
		• Stem cell markers: feline anti-CD4 PE, anti-feline CD5 biotin and streptavidin APC		• Single dose: 0.3 mL PBS containing 10⁶ ASCs (both lanes)
Lee et al. (2014)	BLM-induced pulmonary fibrosis (PF)	• Pre-clinical	• Mices	• Culture-expanded xerogenic adipose tissue-derived MSCs	• Follow-up: mices were euthanized on day 16. Lungs were collected 2 weeks after the last dose of ASCs that occurred on day 14.	BLM-ASC treatment resulted in a significant decrease in the number of apoptotic and inflammatory cells, as well as a reduction in fibrosis score compared to group only with BLM.	NR (Not reported)	NR
		• 40 mices		• Culture-expanded xerogenic adipose tissue-derived MSCs
		• Did not describe the method of dividing the groups, whether it was randomized or not (control: n= 10)		• Administration IV
				• 4 Doses (1 every 2 weeks for 2 months) single: 3 × 10⁵ ASCs
		• Cytological, histological, immunohistochemical and TUNEL method analysis
		• Inflammatory markers: TGF-b
		• Stem cell markers: (+): CD73 and CD105; (-): CD14, CD34 and CD45
Kim et al. (2014)	Elastase-induced pulmonary emphysema	• Pre-clinical	• Mices	• Xerogenic MSCs derived from human adipose tissue, expanded by culture	• Follow-up: Mices were euthanized after 1, 4, 24, 72 and 168 h.	The results show that injected MSCs were observed 1 and 4 h after injection and more MSCs remain in the emphysema lungs.	NR (Not reported)	NR
		• NR the number of Mices
		• NR randomization of group division
		• NR randomization of group division		• Administration IV
		• Image and molecular analysis (PCR)		• Single dose: 5 × 10⁵ ASCs in 100 μL saline
		• Image analysis after 1, 4, 24, 72 and 168 h.		• Stem cell markers: NR
Trzil et al. (2014)	Asthma	• Pre-clinical	• Cats	• Allogeneic cryopreserved MSCs derived from adipose tissue of animal origin, expanded by culture	• Follow-up: Allergen challenges were performed weekly for 4 months after the first infusions. Subsequent challenges were performed bimonthly between months 4 and 8 and monthly from 8 months until the end of the study.	When given after the development of feline chronic allergic asthma, MSCs have failed to reduce airway inflammation. However, repeated administration of MSCs at baseline reduced airway remodeling at month 8 CT, although it was not maintained at month 12.	∼1 month after study completion, one cat developed an aggressive sarcoma. post-death exam confirmed spindle cell sarcoma without evidence of other malignant or metastatic disease.	None
		• 9 cats
		• RCT- control group (4)
		• Clinical analysis, biochemistry, immunohistochemistry, cytology and imaging		• Administration IV
				• 6 doses (2 × /month): 3.64 × 106 to 2.50 × 10⁷ MSCs (average of 1.44 × 107 MSCs alive / infusion)
		• Inflammatory markers: IL10, IgE, lymphocytes and eosinophils in BALF
		• Company-proven stem cells
Dong et al. (2015)	Radiation-induced lung injury (LP)	• Pre-clinical	• Mices	• Xerogenic MSCs derived from human adipose tissue, expanded by culture	• Follow-up: Mices were euthanized on day 3, after 1 week, 2 weeks, 4 weeks, 12 weeks and 24 weeks to perform the necessary analyses.	The results confirmed that mesenchymal stem cells have the potential to limit pulmonary fibrosis after exposure to ionizing irradiation.	NR (Not reported)	NR
		• First part: 108 Mices
		• Second part: 48 mices
		• First part control: 12 (did not specify group division technique)		• Administration IV
				• Single dose: 5 × 10⁶ ASCs (2 h after irradiation)
		• Control second part: 27 mices (did not specify group division technique)
		• Biochemical, immunohistochemical and histopathological analysis
		• Inflammatory markers: TGF-β1, TNF-α, PGE2, HGF, IL-10, COX1 enzyme, COX2 enzyme and IGF
		• Stem cell markers: CD11b, CD19, CD34, CD45, CD73, CD90, CD105 and HLA-DR....
Fikry et al. (2015)	MTX-induced pulmonary fibrosis (PF)	• Pre-clinical (comparative)	• Mices	• Allogeneic MSCs derived from adipose tissue and culture-expanded rat bone marrow.	• Follow-up: mices were euthanized after 6 weeks	Both BM-MSCs and ASCs exerted antifibrotic effects on MTX as a model of pulmonary fibrosis, which can be attributed to their antioxidant and anti-apoptotic properties, therefore, they can be presented as promising candidates for the treatment of pulmonary fibrosis.	NR (Not reported)	NR
		• 40 mices
		• RCT - control group (8)
		• Biochemical, immunohistochemical and histopathological analysis		• Administered intravenously
				• Low dosage: 2 × 10⁶ cel.
		• Inflammatory and oxidative stress markers: IL4, TGF-b1, (MDA, GSH, SOD).		• High dosage: 4 × 10⁶ cel
		• Stem cell markers (+): CD90 and CD105 and (-): CD34		• High dosage: 4 × 10⁶ cel
Perlee et al. (2019a)	Pneumossepsis caused by Klebsiella pneumoniae	• Pre-clinical	• Mices	• MSCs derived from adipose tissue not reported origin, expanded by culture as well as cryopreserved	• Follow-up: Analyzes were performed after euthanasia. Mices infused with ASCs 1 h after infection were sacrificed 4 h or 16 h after pneumonia induction; mices infused with ASCs 6 h after infection were sacrificed 48 h after pneumonia induction.	These data indicate that ASC-associated tissue factor is responsible for systemic activation of coagulation after ASC infusion, but not for the formation of microthrombi in the lungs or for the antibacterial effects.	NR (Not reported)	NR
		• Mices (does not say total amount)
		• Has a control group, but does not specify group division methodology (4‒8)
				• Administration IV
				• High single dose: 1 × 10⁶ ASCs (1 or 6 h after infection)
		• Biochemical, immunohistochemical and histopathological analysis		• Low single dose: 0.4 × 10⁶ cells, 6 h after infection
		• Inflammatory markers: Fibrin
		• Stem cell markers: CD32, CD45 mAb, CD90 mAb, CD16
Perlee et al. (2019b)	Pneumossepsis caused by Klebsiella pneumoniae	• Pre-clinical	• Mices	• Allogeneic MSCs derived from adipose tissue not reported origin, expanded by culture	• Follow-up: Mices were euthanized 16 or 48 h after pneumonia infusion	Both cultured and cryopreserved ASCs were able to reduce bacterial growth and dissemination during K. pneumoniae-induced pneumosepsis, with cryopreserved cells exerting a faster effect at the primary site of infection and with a dose-dependent effect.	NR (Not reported)	NR
		• 50 mices
		• RCT ‒ control group (10)
		• Biochemical, immunohistochemical and histopathological analysis		• Administration IV
				• High single dose: 1 × 10⁶ ASCs, 1 or 6 h after infection
		• Inflammatory markers: IL-1β, IL-6, TNF-α, MIP-2, MPO, E-selectin, VCAM-1 and MCP-1		• Low single dose: 0.4 × 10⁶ cel. 6 h after infection
		• Stem cell markers: CD32, CD45 mAb, CD90 mAb, CD16		• Low single dose: 0.4 × 10⁶ cel. 6 h after infection
Jiang et al. (2015)	Radiation-induced lung injury (LP)	• Pre-clinical	• Mices	• Allogeneic MSCs derived from rat adipose tissue, expanded by culture	• Follow-up: days 1, 3, 7, 14 and 28	ASCs reduced serum levels of pro-inflammatory cytokines, increased levels of anti-inflammatory and regulated the expression of pro- and anti-apoptotic mediators to protect lung cells.	NR (Not reported)	NR
		• 90 Mices
		• RCT ‒ control group (30)
		• Biochemical, immunohistochemical, localization (fluorescence microscopy) and histopathological analysis		• Administration IV
				• Single dose: 5 × 10⁶ ASCs (2 h after irradiation)
		• Inflammatory markers: IL-1, IL-6, IL-10, TNF-α, TGF-β1 and HGF
		• Stem cell markers: CD11b-PE, CD29-PE, CD44-FITC and CD45-APC.
Mao et al. (2015)	Acute Lung Injury (ALI)	• Pre-clinical	• Mices	• Allogeneic MSCs derived from adipose tissue of animal origin, expanded by culture	• Follow-up: 24 h after P. aeruginosa infection	ASCs exhibited protective effects against pulmonary P. aeruginosa infection.	NR (Not reported)	NR
		• NR number of Mices
		• NR randomization and division of groups
		• Clinical, biochemical, immunohistochemical and histopathological analysis		• Administration IV
				• High single dose: ∼5 × 10⁶ ASCs
		• Inflammatory markers: KGF, Ang-1, IGF-1, PGE2, COX2 and 15-PGDH		• Low single dose: ∼5 × 10⁵ ASCs
		• Stem cell markers: (+): CD34, CD45; (-): CD90, CD105		• Low single dose: ∼5 × 10⁵ ASCs
Tashiro et al. (2015)	BLM-induced pulmonary fibrosis (PF)	• Pre-clinical	• Mices	• Allogeneic MSCs derived from the adipose tissue of young mices, expanded by culture	• Follow-up: all mices were euthanized on day 21 for analysis.	The fibrosis score in the lungs of mices that received BLM was decreased in those treated with yASCs, however, the score in those treated with oASCs remained high.	NR (Not reported)	NR
		• Mices (did not say quantity)
		• Has control (did not specify group division technique)		• Administration IV
		• Has control (did not specify group division technique)		• Single dose: 5 × 10⁵ ASCs
		• Biochemical, immunohistochemical and histopathological analysis
		• Inflammatory markers: TGF-β, integrin-αv, TNF-α, VEGF, Nrf2, MMP-2, ROS, and IGF
		• Stem cell markers: CD90, CD205, CD29, Sca1, CD79α, CD45, CD14 and CD11
Reddy et al. (2016)	BLM-induced pulmonary fibrosis (PF)	• Pre-clinical (comparative)	• Mices	• Xerogenic MSCs derived from human adipose tissue, subjected to enzymatic degradation	• Follow-up: all mices were euthanized on day 24 for analysis.	Survival was significantly prolonged and better in mices treated with ASC than pirfenidone. After the infusions, the disease characteristics disappeared significantly on day 21, it also demonstrated homing and graft potential towards the damaged lung tissue, being detected on day 24 after administration.	NR (Not reported)	NR
		• 50 mices
		• RCT - control group (10)
		• Radiological, biochemical, immunohistochemical and histopathological analysis		• IV administration, 3 doses (3 days between)
				• Dose: 40 × 10⁶ cel./kg (equivalent in a human to 2 × 10⁶/kg)
		• Inflammatory markers: IL2, IL1b, TNF-α, TGF β, bFGF, CTGF, CoL3a1, CoL1a1, MMP-TIMP
		• Stem cell markers: CD34, CD45, CD73, CD90, CD105, CD166
Pedrazza et al. (2017)	Acute Lung Injury (ALI)	• Pre-clinical	• Mices	• Allogeneic MSCs derived from adipose tissue of animal origin, expanded by culture	• Follow-up: After 7 days, animals that were still alive were anesthetized. Analyzes were performed 12 h after administration of ASCs.	The mices that received MSCs had a significantly higher survival rate compared to the LPS group, improvements in cytological, histological and biochemical analyses, indicating a possible action of MSCs via neutrophils.	NR (Not reported)	NR
		• NR total number of mices
		• NR randomization or division of groups
		• Cytological, histological, immunohistochemical and biochemical analysis		• Retro orbital IV administration
				• Single dose: 5 × 10⁵/100 μL PBS
		• Inflammatory markers: IL-6, TNF-α, IL-10, COX-2, GAPDH enzyme, NF-κB
		• Stem cell markers: (+): CD73 and CD105; (-): CD14, CD34 and CD45
Chen et al. (2018)	Silicosis-induced pulmonary fibrosis (PF)	• Pre-clinical	• Mices	• Allogeneic MSCs derived from rat adipose tissue, expanded by culture	• Follow-up: 28 days	Treatment with transplant ASCs led to a remissive effect on pulmonary fibrosis.	NR (Not reported)	NR
		• 20 mices
		• RCT - control group (5)
		• Biochemical, immunohistochemical and histopathological analysis		• Administration IV
				• Single dose: 5 × 10⁵ ASCs (24 h after exposure to silica)
		• Inflammatory markers: TNF-α, IL-1β, IL-6 and IL-10
		• Stem cell markers: CD44, CD45, CD90, CD73 and CD11b
Felix et al. (2020)	BLM-induced pulmonary fibrosis (PF)	• Pre-clinical	• Mices	• Allogeneic MSCs derived from adipose tissue of animal origin, expanded by culture and ASC-MC.	• Follow-up: 14 and 21 days	Mices that were injected with MSCs and MC showed improvement in general status, in addition to presenting an early anti-inflammatory action and improvement in fibrotic markers.	NR (Not reported)	NR
		• 40 mices
		• RCT - control group (10)
		• Clinical, biochemical, immunohistochemical and histopathological analysis		• Administration IV
				• Single dose high MSC: 1 × 10⁶ ASCs in 0.2 mL of serum free medium (10 days after induction)
		• Inflammatory and fibrotic markers: fibrinogen, Von Willebrand factor, PDGF, NOS, IL-17, TGF-β, VEGF, endothelin-1 and the immunogenic Col. V in lung tissue of mices with MBL lesion after treatment with MSCs		• DU MC: 200 μL, derived from 1 × 10⁶ cel. (10 days after induction)
		• Stem cell markers: CD34, CD45, CD90
Radwan et al. (2020)	Amiodarone-induced pulmonary fibrosis (PF)	• Pre-clinical	• Mices	• Allogeneic MSCs derived from culture-expanded rat adipose tissue	• Follow-up: At the end of 12 weeks in order to confirm induction of pulmonary fibrosis, three animals were randomly euthanized from the control and amiodarone-treated groups. After the end of the experimental period (2 months), all animals fasted for 12 h and blood samples were collected	Treatment with ASC resulted in improvement of biochemical and histopathological parameters.	NR (Not reported)	NR
		• 40 mices
		• RCT - control group (10)
		• Biochemical, immunohistochemical and histopathological analysis		• Administered intravenously
				• Low dosage: 2 × 10⁶ cel.
		• Inflammatory markers: CC16 protein, CK19 protein, αSMA.		• High dosage: 4 × 10⁶ cel.
		• Stem cell markers (+): CD90 and CD105; and (-): CD34		• High dosage: 4 × 10⁶ cel.

Authors	Pathology	Effectiveness analysis					Safety analysis
Authors	Pathology	Study method	Participants	Intervention	Follow-up	Results observed	Serious adverse events	Light adverse events
Zheng et al. (2014)	ARDS	• Single-center, randomized, double-blind, placebo-controlled trial.	• 12 Patients with ARDS aged at least 18 years and diagnosed within 48 h with a PaO2/FiO2 ratio of < 200.	• Follow-up: days 1, 3, 5, 7, 14 and 28 (or until hospital discharge or death, whichever comes first).	• Adipose tissue-derived allogeneic MSCs expanded by culture in patient serum	There were no infusion toxicity or serious adverse events related to MSC administration and there were no significant differences in the overall number of adverse events between the two groups.	None	One patient in each group had diarrhea one day after treatment resolved within 48 h. One patient in the MSC group developed a rash in the chest area after the infusion and resolved spontaneously over 24 h
		• 12 Patients			• Administered IV
		• RCT - control			• DU: 1 × 10⁶ /kg.
		• Primary endpoint: occurrence of adverse events. Secondary endpoints included the following: PaO2/FiO2 ratio, length of stay, days without ventilation, days without ICU on day 28, IL-6 and IL-8.	• Average age in the MSCS group: 66.7 years \| in control: 69.8 years		• CD73, CD90, CD105, CD34, CD45 and HLA-DR....
Leng et al. (2020)	SARS-COV-2	• Concept proof	• 7 patients with COVID (CRP +) and unresponsive to conventional therapies with persistent worsening of the condition	• Average follow-up: 14 days	• MSCs of undefined origin	No acute infusion-related or allergic reactions were observed within two hours of transplantation. Likewise, no delayed hypersensitivity or secondary infections were detected after treatment.	None	None
		• 7 Patients			• Administered intravenously
		• RCT			• Single dose: 1 × 10⁶ /kg.
		• 1st safety endpoint: secondary infection and life-threatening adverse events. 1st efficacy endpoint: level of variation in cytokines, serum C-reactive protein and oxygen saturation. 2nd efficacy endpoint: total lymphocyte and subpopulation count, chest CT, respiratory rate, patient symptoms, therapeutic measures and their results.			• Does not describe stem cell (CD) markers
			• Ages ranging between: 45 and 75 years old		• Does not describe stem cell (CD) markers
Sánchez-Guijo et al. (2020)	COVID-19	• Concept proof	• 3 Patients with COVID-19 (CRP + Rx or CT) and on mechanical ventilation	• Average follow-up: 14 days	• Culture-expanded adipose-derived allogeneic MSCs	Treatment with ASC proved to be safe and resulted in a decrease in inflammatory parameters, as well as an increase in lymphocytes, especially in those patients with clinical improvement.	None	None
		• 13 Patients with COVID-19 (CRP + CX or chest CT) on mechanical ventilation			• Culture-expanded adipose-derived allogeneic MSCs
					• Administered IV
					• Average number of cells per dose: 0.98 (IQR 0.5) × 10⁶ /kg.
		• No control group	• Average age: 60 years old
		• Clinical and radiological analysis	• Average time between MSC dose and extubation: 7 days		• 1 pct: 3 doses; 2pcts: 2 two; 10 pcts: 2 doses
		• Laboratory analysis of inflammatory markers: C-reactive protein, LDH, d-dimer and ferritin	• Average time between MSC dose and extubation: 7 days		• + CD90 and CD105; - CD34

Title (year)	Study method	Population	Intervention	Comparator	Outcomes	Status
Safety and Efficacy of Adipose Derived Stem Cells for Chronic Obstructive Pulmonary Disease (2014)	• Phase I/II Open-label, single group assignment, Non-Randomized, Multi-center Study	• 26 patients (Age 18 to 85, prior diagnosis of moderate to severe COPD; GOLD IIa, III, IV; Cognitive competitiveness; life expectancy > 6 months, written informed consent)	• 100‒240cc of lipoaspirate will be extracted from the patient. The SVF will be isolated with minimal manipulation. The cell pellet will be reconstituted in saline solution and administered intravenously to the patient as a single dose of autologous adipose derived stem cells. The dosage was not described	None	• Primary outcomes: FEV1 Decline [Time Frame: 12 months] and Number of Adverse Events [Time Frame: 12 months]	Completed
				None	• Secondary outcomes: Secondary Efficacy Objective [Time Frame: 12 Months]	Completed
Safety, Tolerability and Preliminary Efficacy of Adipose Derive Stem Cells for Patients With COPD (2014)	• Phase I Open- Label, single group assignment, study to assess safety and tolerability	• 9 patients (males and females ≥18 years. Cognitive competitiveness. Diagnosis of at least moderate, COPD, Diffusing capacity impairment, assessed by single breath test, life expectancy > 12 months, written informed consent, non-smoker or past smoker, with 20 pack-years or more history)	• 100‒240cc of lipoaspirate will be extracted from the patient. The SVF will be isolated with minimal manipulation. The cell pellet will be reconstituted in saline solution and administered intravenously to the patient as a single dose of autologous adipose derived stem cells. The dosage was not described	None	• Primary outcomes: Safety of adipose derived stem cells (ADSC) in Patient with COPD [Time Frame: 12 months]	Terminated
				None	• Secondary outcomes: Efficacy of ADSC in improving Shortness of Breath (SOB) [Time Frame: 2, 6 and 12 months]; Efficacy of ADSC In Pulmonary Function Test (PFTs) [Time Frame: 2, 6, 12 months]; Efficacy of adipose derived stem cell in 6 MWT [Time Frame: 2, 6, 12 months]; Efficacy of adipose derived stem cells in patient's perceived exertion [Time Frame: 2, 6, 12 months]; Efficacy in Quality of life using George's Respiratory Questionnaire [Time Frame: 2, 6, 12 months]; Efficacy in Quality of life using the Chronic Respiratory questionnaires [Time Frame: 2, 6, 12 months].	Terminated
Adipose Derived Stem Cells Transplantation for Chronic Obstructive Pulmonary Disease (2016)	• Phase I/II open- label single-dose study in subjects with significant COPD.	• 20 patients (Age 40 to 80 + prior diagnosis of moderate to severe COPD GOLD IIa, III, IV)	• Autologous SVF and PRP will be transfused into 20 COPD patients.	None	• Primary outcomes: SGOT [Time Frame: 1 month], SGPT [Time Frame: 1 month]	Unknown
				None	• Secondary outcomes: Respiration rate [Time Frame: 1 month, 6 months, 12 months], 6 min walk test [Time Frame: 1 month, 6 months, 12 months],rates of panic attacks [Time Frame: 1 month, 6 months, 12 months], CRP concentration [Time Frame: 6 months, 12 months].	Unknown
Adipose Derived Cells for Chronic Obstructive Pulmonary Disease (2014)	• Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects	• 0 patients	• Adipose Derived Stem Cells. The dosage or origin was not described	None	• Primary outcomes: assess safety	Withdrawn
		• 0 patients		None	• Secondary outcomes: efficiency in improving the disease pathology of patients with diagnosed with chronic obstructive pulmonary disease	Withdrawn
Safety and Efficacy of Adipose Derived Stem Cells for Chronic Obstructive Pulmonary Disease (2012)	• Phase I/II Open-label, Non-Randomized, Multi-Center Study	• 0 patients	• SVF harvested from Autologous Adipose Tissue will be deliver after processing via IV and Inhalation	None	• Primary outcomes: Functional Capacity improved compared to baseline [Time Frame: 3 months, 6 months], Number of adverse events [Time Frame: 3 months, 6 months]	Withdrawn (company dissolved)
	• Phase I/II Open-label, Non-Randomized, Multi-Center Study	• 0 patients		None	• Secondary outcomes: Quality of Life improved compared to baseline [Time Frame: 3 months, 6 months].	Withdrawn (company dissolved)
Cell Therapy in Advanced Chronic Obstructive Pulmonary Disease Patients (2015)	• Phase I/II randomized, open- label, placebo-control study	• 20 patients (COPD patients with persistent dyspnea in stage 2 or 3 of the dyspnea scale score; Eligibility for pulmonary rehabilitation program; No smoking or smoking cessation for at least 6 months, abscense of emphysema)	• BMMC: 1 × 10^8 B.M. in 30 mL saline IV.	No interventions will be performed other than conventional (in-course) treatment.	• Primary outcomes: Pulmonary morphology [Time Frame: 9 months after procedure]	Unknown
			•ASC: 1 × 10^8 ASC in 30 mL saline IV.
			•BMMC + ASC: 5 × 10^7 ASC + 5 × 10^7 B.M. in 30 mL saline IV.		• Secondary outcomes: Pulmonary morphology [Time Frame: 9 months after procedure]; Pulmonary function [Time Frame: 12 months after procedure]
Use of Autologous, Adult Adipose-Derived Stem/Stromal Cells In Chronic Lung Disorders (ADcSVF-COPD) (2016)	• Phase I/II non-randomized, single-blind, study	• 100 patients (18‒80 years, prior diagnosis of moderate to severe COPD; GOLD IIa, III, IV);no positve hepatites)	• Experimental: Isolation and IV administration of cellular stem/stromal cells from subdermal adipose-derived cellular stromal vascular fraction. Intervention: Procedure: SVF	None	• Primary outcomes: Safety ‒ Pulmonary Function [Time Frame: 12 months Evaluate Function and Adverse Events], Change from Baseline Respiratory Rate [Time Frame: 1 month, 6 month, 1 year].	Enrolling by invitation
	• Phase I/II non-randomized, single-blind, study		• Experimental: Normal Saline IV Arm 3 with SVF cells	None	• Secondary outcomes: GOLD Classification [Time Frame: 1 year]; Change from baseline 6 Min Walk Test [Time Frame: 12 Months]; Exercise capacity measured by distance a patient can walk in 6 min timeframe; Change from Baseline Lung X-Ray [Time Frame: 6 months, 12 months]; Change from Baseline SGOT Blood Testing [Time Frame: 1 Month]; Change from Baseline SGPT Blood Testing [Time Frame: 1 Month]; Pulmonary Function Testing [Time Frame: Baseline, 6 Months].	Enrolling by invitation
Autologous Adipose-derived Stem Cells (AdMSCs) for COVID-19 (2020)	• Phase II randomized, double-blind, placebo-control study conducted in multiple clinic facilities	• 200 participants (> 18 years; male or female; have banked AdMSCs in Celltex; written informed consent; highly susceptible to SARS-CoV-2 infections, no terminal stages; no previous COVID-19 history, SARS-CoV-2 RT-PCR or equivalent tests negative; SARS-CoV-2 IgM and IgG negative)	• Three doses of 200 million autologous adipose derived mesenchymal stem cells via intravenously infusion every three days	• Three doses of placebo via intravenously infusion every three days.	• Primary outcomes: Assessment of the total number of AEs/SAEs related and non-related with the medication [Time Frame: 6 months]; Proportion of AEs/SAEs related and non-related with the ASCs infusions as compared to the control group [Time Frame: 6 months]; COVID-19 incidence rates [Time Frame: 6 months]	Not yet recruiting
					• Secondary outcomes: Proportion of SARS-CoV-2 infected subjects testing [Time Frame: 6 months]; Proportion of mild, classic, severe and critically sever symptomatic SARS-CoV-2 infected subjects [Time Frame: 6 months]; Change of proportion of SARS-Cov-2 infected subjects IgM/IgG + against SARS-CoV-2. [Time Frame: 6 months]; Change of lymps count from the baseline [Time Frame: 6 months]; Change of PaO2 from the baseline [Time Frame: 6 months]; Compare the proportion of severe COVID-19 pneumonia cases development [Time Frame: 6 months]; COVID-19 mortality rates [Time Frame: 6 months]; Change of CRP (mg/L), d-dimer (mg/L, Procalcitonin (ug)/L, pro-BNP (pg/mL), BI (mg/dL), Cr (mg/dL), from the baseline [Time Frame: 6 months]; Change in cytokine panels (IL-1β, IL-6, IL-8, IL-10, TNFα) from the baseline [Time Frame: 6 months]; Proportion of SARS-CoV-2 RT-PCR positive to negativity [Time Frame: 6 months]; Quantifying viral RNA in stool for baseline and final follow-up. [Time Frame: 6 months].	Not yet recruiting
Clinical Study for Subjects With COVID-19 Using Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs) (2021)	• Phase II randomized, double blind and placebo controled study conducted initially in a single clinic facility.	• 30 participants (> 18 years; male or female; Diagnosed as COVID-19 based upon SARS-CoV-2 RT-PCR + test; Clinical diagnosis meets severe and/or critical parameters; Male participants must be willing to ensure their partners do not become pregnant either by practicing abstinence or the use of condoms during sexual activity)	• Three separate doses of 200 million allogeneic adipose-derived mesenchymal stem cells via intravenously infusion on days 0, 3, and 6 with a total of 600 million AdMSCs during 7 days in addition to their standard of care.	• The control group will receive placebo infusion on day 0, 3 and 6 along with standard of care.	• Primary outcomes: Frequency and nature of adverse events occurring during the study based on the rate of all ASC associated AEs in all subjects. [Time Frame: 6 months]; Safety for ASCs based upon incidence of all AEs [Time Frame: 6 months]; Comparison the mortality rate between treating group vs. control group [Time Frame: 6 months]	Not yet recruiting
					• Secondary outcomes: Change of SOFA score as compare to the baseline Time Frame: 6 months]; Organ functional tests including blood specific enzymes and proteins [Time Frame: 6 months]; Days of weaning from mechanical ventilation [Time Frame: 6 months]; Duration (days) of ICU monitoring [Time Frame: 6 months]; Duration (days) of vasoactive agent's usage [Time Frame: 6 months]; Days of hospitalization [Time Frame: 6 months]; Proportions of SARS-CoV-2 RT-PCR change to negative from respiratory tract specimens using CDC standard method [Time Frame: 6 months]; Proportions of quantifying viral RNA in stool change to negative in final follow-up using CDC standard method [Time Frame: 6 months]; Proportions of blood SARS-CoV-2 antibodies IgM/IgG show positive [Time Frame: 6 months].	Not yet recruiting
Clinical Study of Adipose Derived Mesenchymal Stem Cells for Treatment of Pulmonary Arterial Hypertension (2019)	• Phase I/II, randomized, double masked, parallelly assignmented study	• 60 participants (40‒75years; male or female; COPD with moderate to severe pulmonary hypertension; lifetime > 6 months; signed the informed consent in person)	• The MSCs of 1 × 10×6/kg will be given in Central venous catheterization for injection at a total 100 mL. The injection cycle was once every week of two times.	• Conventional drug therapy (expectorant, bronchodilator)	• Primary outcomes: Change in Pulmonary Vascular Resistance from Baseline [Time Frame: Baseline, 4, 12 and 24 weeks]	Unknown
				• Conventional drug therapy (expectorant, bronchodilator)	• Secondary outcomes: Change from Baseline in Participant Quality of Life Using the ASCs [Time Frame: Baseline, 4, 12 and 24 weeks]; Change in Plasma NT-pro-BNP levels [Time Frame: Baseline, 4, 12 and 24 weeks]; Change in the IL-1β, IL-6, PGE-2, TGF-β, TNF-α and IGF-1 (ng/ul) [Time Frame: Baseline, 4, 12 and 24 weeks]; Incidence of Treatment Adverse [Time Frame: Baseline, 4, 12 and 24 weeks]; Change in Six Minute Walk distance [Time Frame: Baseline, 4, 12 and 24 weeks]	Unknown
Evaluate Safety and Efficacy of Intravenous Autologous ADMSc for Treatment of Idiopathic Pulmonary Fibrosis (2014)	• Phase I/II, Prospective, Multicentric, Open Label, Randomized, Interventional Study	• 60 participants (40‒75years; male or female; COPD with moderate to severe pulmonary hypertension; lifetime > 6 months; signed the informed consent in person)	• Single dose of SVF IV;	• CCO ≤10 mg/day or ≤20 mg alternating days + Immunosuppressants 2 mg/kg/day, not exceeding 150 mg/day + Antioxidants up to 1800 mg/day + Pirfenidone up to 1200 to 1800 mg/day.	• Primary outcomes: Incidence of treatment emergent AEs in the study [Time Frame: 9 Month].	Unknown
			• 3 IV doses of 2 million/kg ASCs each, given at weekly intervals.
					• Secondary outcomes: Change in predicted FVC% at EOS [Time Frame: 9 Month]; Change in predicted DLCO% at EOS [Time Frame: 9 Month]; Change in the 6MWT at EOS [Time Frame: 9 Month]; Changes in the disease extent and severity as reflected by HRCT (64 SLICE) at EOS from randomization [Time Frame: 9 Month].
Study of Intravenous Administration of Allogeneic Adipose Stem Cells for COVID-19 (CoronaStem1) (2020)	• Phase I, open label, single group comparison with cohort of contemporaneous non-treated patients.	• 10 participants (Admitted to hospital as inpatient; respiratory distress; bilateral lung infiltrates; supplemental oxygen started but NOT intubated or ventilated; COVID-19 positive antigen test; time from enrollment to treatment < 24 h; age: 18‒80 years; gender: any; suitability for cellular therapy; preserved cognitive function)	• Adipose stem cells derived from screened donor lipoaspirate and culture expanded. The dosage was not described.	None	• Primary outcomes: Frequency of all AEs [Time Frame: Through study completion, an average of three months]; Frequency of infusion related SAEs [Time Frame: 6 h post infusion]; Frequency of SAEs [Time Frame: Through study completion, an average of three months];	Completed
				None	• Secondary outcomes: Mortality [Time Frame: Study days 0‒28]; Ventilator Free Days [Time Frame: Study days 0‒28]; ICU Free Days [Time Frame: Days 0 through 28]; Total Hospital Days [Time Frame: Days 0 through discharge, an average of 28 days]; Total ICU Days [Time Frame: Days 0 through discharge, an average of 28 days]; Improvement in Oxygenation [Time Frame: Study days 0, 2, 4, 6]	Completed
Adipose-derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome (2013)	• Phase I, randomized, triple blinded, parallelly assignmented study.	• 20 participants (ARDS diagnosed using Berlin definition; at least 18 years of age; acute onset of ARDS; Bilateral opacities in chest radiography; No cardiac failure; PaO2/FiO2 ratio < 200)	• One dose of 1 × 10^6 allogeneic adipose-derived mesenchymal stem cells/kg body weight intravenously within 48 h of enrollment.	• One dose of Intravenous saline infusion	• Primary outcomes: Compare the adverse events between mesenchymal stem cell treatment and placebo groups [Time Frame: From day 0 at the start of treatment to day 28].	Unknown
				• One dose of Intravenous saline infusion	• Secondary outcomes: Hospital indices by treatment group [Time Frame: From admission to discharge]	Unknown
Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 "Long Haul" Pulmonary Compromise (2021)	• Phase IIa, randomized, open-label, parallelly assignmented study.	• 0 participants	• IV iASCs (∼18.5 million cells) on Day 0, Day 2, and Day 4.	None	• Primary outcomes: Change in 6MWD at Day 60 [Time Frame: Baseline to Day 60];	Withdrawn (Replaced by a different protocol.)
		• 0 participants	• IV ASCs (∼37 million cells) on Day 0, Day 2, and Day 4.	None	• Secondary outcomes: Change in 6MWD at Day 30 [Time Frame: Baseline to Day 30]; Change in Pulmonary Function Tests (PFTs) [Time Frame: Baseline to Day 30 and Day 60]; Change in oxygenation [Time Frame: Baseline to Day 30 and Day 60]; Change in biomarker levels [Time Frame: Baseline through Day 30]	Withdrawn (Replaced by a different protocol.)
A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19 (2020)	• Phase II, Open Label, Single-Center, Clinical Trial	• 56 participants (Men, and women > 65 years OR works in high-risk environment OR has underlying conditions; have previously banked their cells at Hope Biosciences; no signs or symptoms of infection, subject provides written informed consent; agrees to the collection of venous blood per protocol.)	• Five IV infusions of autologous, adipose-derived mesenchymal stem cells.	None	• Primary outcomes: Incidence of hospitalization for COVID-19 [Time Frame: Week 0 through week 26]; Incidence of symptoms for COVID-19 [Time Frame: week 0 through week 26]	Completed
	• Phase II, Open Label, Single-Center, Clinical Trial			None	• Secondary outcomes: Absence of upper/lower respiratory infection [Time Frame: Weeks 0 through 26]; Glucose, Ca, Albumin, Total proteína, Na, total carbono dioxide, Cl, AP, total BI, BUN, ALT,AST, Cr,Ht, MCHb, CHb, MCV, Platelets, CRP [Time Frame: Weeks 0, 6, 14, 26]; White blood cells [Time Frame: Weeks 0, 6, 14, 26]; Red blood cells [Time Frame: Weeks 0, 6, 14, 26]; Hb [Time Frame: Weeks 0, 6, 14, 26]; Ht [Time Frame: Weeks 0, 6, 14, 26];; Red cell distribution width [Time Frame: Weeks 0, 6, 14, 26]; Neutro [Time Frame: Weeks 0, 6, 14, 26]; Lymphs, Eos, Mono, Baso, [Time Frame: Weeks 0, 6, 14, 26]; Absolute neutro, Absolute lymphs, Absolute mono, Absolute eos, Absolute baso [Time Frame: Weeks 0, 6, 14, 26]; Immature granulocytes [Time Frame: Weeks 0, 6, 14, 26]; Absolute Immature granulocytes [Time Frame: Weeks 0, 6, 14, 26]; Prothrombin time [Time Frame: Weeks 0, 6, 14, 26]; INR [Time Frame: Weeks 0, 6, 14, 26]; TNFalpha [Time Frame: Weeks 0, 6, 14, 26]; IL-6 and IL-10 [Time Frame: Weeks 0, 6, 14, 26]; SF-36 [Time Frame: Weeks 0, 6, 14, 26]; PHQ-9 [Time Frame: Weeks 0, 6, 14, 26]	Completed
Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Non-COVID-19 Acute Respiratory Distress Syndrome (2021)	• Phase IIa Randomized, Placebo-Controlled Study	• 0 participants	• ASCs IV (two vials or a total of ≈30 million cells) on Day 0, Day 2, and Day 4	• Placebo IV (two vials) on Day 0, Day 2, and Day 4	• Primary outcomes: All-cause mortality rate at Day 28 [Time Frame: Baseline to Day 28];	Withdrawn (Replaced by a different protocol.)
	• Phase IIa Randomized, Placebo-Controlled Study	• 0 participants		• Placebo IV (two vials) on Day 0, Day 2, and Day 4	• Secondary outcomes: All-cause mortality rate at Days 60 and 90; Number of ventilator-free days through Day 28; Number of ICU days through Day 28; Clinical status at Day 28; Change in oxygenation [Time Frame: Baseline to Day 2, Day 4, Day 6, Day 14, Day 28].	Withdrawn (Replaced by a different protocol.)
Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 "Long Haul" Pulmonary Compromise (BR) (2021)	• Phase IIa Randomized, Placebo-Controlled study	• 60 participants (prior laboratory-confirmed SARS-CoV-2 infection; < 1 week negative SARS-CoV-2 test; at least moderate or severe post-COVID-19 pulmonary symptoms for at least 3 months which have resulted in reduced physical functioning compared to pre-COVID-19 status; willing to follow contraception guidelines).	• 2, 4 or 6 MSC vials IV (approximately 15million cells/vial) on Day 0, Day 2, or Day 4 depending on assignment to treatment group: Group A: 2 MSC vials infused on D0 and 2 vials of placebo on D2 and D4; Group B: 2 MSC vials infused on D0 and D2 and 2 vials of placebo on D4; Group C: 2 MSC vials infused on D0 and D4 and 2 vials of placebo on D2; Group D: 2 MSC vials infused on D0, D2 and D4	• 6 vials of placebo will be intravenously infused on Day 0, Day 2, or Day 4.	• Primary outcomes: Change in 6MWD at Day 60 [Time Frame: Baseline to Day 60]	Not yet recruiting
	• Phase IIa Randomized, Placebo-Controlled study				• Secondary outcomes: Change in 6MWD at Day 30 [Time Frame: Baseline to Day 30]; Relief of symptoms on Day 30 and Day 60 [Time Frame: Baseline to Day 30 and Day 60]; Change in Pulmonary Function [Time Frame: Baseline to Day 30 and Day 60]; Change in oxygenation [Time Frame: Baseline to Day 30 and Day 60]; Change in biomarker levels [Time Frame: Baseline to Day 60]	Not yet recruiting
Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Treatment of COVID-19 Acute Respiratory Distress (2021)	• Phase II, Randomized, parallelly assignmented, quadruple blinded study	• 60 participants (prior laboratory-confirmed SARS-CoV-2 infection; < 1 week negative SARS-CoV-2 test; hospitalized with at least "severe" COVID-19-induced ARD or ARDS; requires oxygen supplementation at Screening; willing to follow contraception guidelines).	• ASCs IV (two vials or a total of ≈ 30 million cells) on Day 0, Day 2, and Day 4	• Placebo IV (two vials) on Day 0, Day 2, and Day 4	• Primary outcomes: All-cause mortality rate at Day 28; Incidence of all adverse events (AEs) [Time Frame: Baseline through study completion at Day 90]; Incidence of treatment-emergent adverse events [Time Frame: Baseline through study completion at Day 90]; Incidence of severe adverse events [Time Frame: Baseline through study completion at Day 90]; Incidence of infusion-related adverse events [Time Frame: Baseline to Hour 4]	Recruiting
				• Placebo IV (two vials) on Day 0, Day 2, and Day 4	• Secondary outcomes: All-cause mortality rate at Day 60 and 90; Number of ventilator-free days through Day 28; Number of ICU days through Day 28; Change in clinical status [Time Frame: Baseline to Day 28]; Change in clinical status as assessed using the WHO Clinical Progression Scale (0‒10 scale, where lower score means a better outcome) at Day 28; Change in oxygenation [Time Frame: Baseline to Day 14 Day 28, and Day 60].	Recruiting
Clinical Study to Assess the Safety and Preliminary Efficacy of HCR040 in Acute Respiratory Distress Syndrome (2020)	• Phase I (open label) study and Phase II, randomized, controlled, double-blinded study	• PI: 6 participants with moderate to severe ARDS will be included in 2 sequential cohorts.	• PI: Open label IV dose escalation, 3 patients in cohort 1 (1 million cells/kg) and 3 patients in cohort 2 (2 million cells/kg)	• PI: None	• Primary outcomes: Number of AEs [Time Frame: One year];	Recruiting
		• PII: 20 participants with moderate to severe ARDS will be randomly divided into two groups (control and treated).	• PII: Maximum tolerated dose IV (1 million cells/kg or 2 million cells/kg).	• PII: IV vehicle solution.	• Secondary outcomes: Average stay in the ICU 28 days after the administration of HCR040; SOFA index at 3, 7, 14, 21, and 28 days after the administration of HCR040; Mechanical ventilation-free days 28 days after the administration of HCR040; Percent mortality 28 days after the administration of HCR040; Daily pulmonary mechanics values (Ppl, DP, CRS) [Time Frame: One year]; Determination of lung damage using the Murray scale at day 3, 7, 14 and 28 after the administration of HCR040; Vasopressor-free days 28 days after the administration of HCR040; ICU-free days 28 days after the administration of HCR040	Recruiting
Study of Intravenous Administration of Allogeneic Adipose-Derived Mesenchymal Stem Cells for COVID-19-Induced Acute Respiratory Distress (2021)	• Phase II, Randomized, parallelly assignmented, double blinded study	• 0 participants	• 1 × 10^6 MSCs/kg or 1.5 × 10^6 MSCs/kg, depending on CRP level	• Equivalent volume of placebo will be administered	• Primary outcomes: Mortality at Day 28;	Withdrawn (Replaced by a different protocol.)
		• 0 participants		• Equivalent volume of placebo will be administered	• Secondary outcomes: Mortality at Days 60 and 90; Number of ventilator-free days [Time Frame: Randomization through Day 28]; Improvement in oxygenation [Time Frame: Randomization to Day 2, Day 4, Day 6, Day 14, Day 28]; SOFA score at Day 28.	Withdrawn (Replaced by a different protocol.)
A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Allogeneic Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19 (2020)	• Randomized, Double-Blind, Placebo-Controlled Single-Center Clinical Trial	• 55 participants (all gender, > 18 years, high-risk potential exposure to COVID-19 job,no signs or symptoms of infection, agrees to the collection of venous blood per protocol, agrees to conformational testing for SARS-CoV-2 before end of study.	• 5 intravenous infusions of ASCs at 200 million cells/dose each. Infusions will occur at weeks 0, 2, 6, 10, and 14.	• 5 intravenous infusions of placebo intervention (saline). Infusions will occur at weeks 0, 2, 6, 10, and 14.	• Primary outcomes: Incidence of hospitalization for COVID-19 [Time Frame: week 0 through week 26]; Incidence of symptoms associated with COVID-19 [Time Frame: week 0 through week 26]	Completed
			• 5 intravenous infusions of100 million cells/dose each. Infusions will occur at weeks 0, 2, 6, 10, and 14.
			• 5 intravenous infusions of 50 million cells/dose each. Infusions will occur at weeks 0, 2, 6, 10, and 14.,		• Secondary outcomes: Absence of upper/lower respiratory infection [Time Frame: week 0 through week 26]; Leukocyte differential [Time Frame: weeks 0, 6, 14, 26]; CRP [Time Frame: weeks 0, 6, 14, 26]; TNF alpha [Time Frame: weeks 0, 6, 14, 26]; IL-6 [Time Frame: weeks 0, 6, 14, 26]; IL-10 [Time Frame: weeks 0, 6, 14, 26]; Glucose [Time Frame: weeks 0, 6, 14, 26]; Ca [Time Frame: weeks 0, 6, 14, 26]; Albumin [Time Frame: weeks 0, 6, 14, 26]; Total protein [Time Frame: weeks 0, 6, 14, 26]; Na: [Time Frame: weeks 0, 6, 14, 26]; Total carbon dioxide [Time Frame: weeks 0, 6, 14, 26]; K [Time Frame: weeks 0, 6, 14, 26]; Cr [Time Frame: weeks 0, 6, 14, 26]; BUN [Time Frame: weeks 0, 6, 14, 26]; Cr[Time Frame: weeks 0, 6, 14, 26]; AP [Time Frame: weeks 0, 6, 14, 26]; ALT [Time Frame: weeks 0, 6, 14, 26]; Total BI [Time Frame: weeks 0, 6, 14, 2]; white blood cells [Time Frame: weeks 0, 6, 14, 26]; red blood cells [Time Frame: weeks 0, 6, 14, 26]; Hb [Time Frame: weeks 0, 6, 14, 26]; Ht [Time Frame: weeks 0, 6, 14, 26]; MCV [Time Frame: weeks 0, 6, 14, 26]; MCHb [Time Frame: weeks 0, 6, 14, 26]; MCHb concentration [Time Frame: weeks 0, 6, 14, 26]; red cell distribution width [Time Frame: weeks 0, 6, 14, 26]; neutro [Time Frame: weeks 0, 6, 14, 26]; Lymphs [Time Frame: weeks 0, 6, 14, 26]; Mono [Time Frame: weeks 0, 6, 14, 26]; Eos [Time Frame: weeks 0, 6, 14, 26]; Baso [Time Frame: weeks 0, 6, 14, 26]; Absolute neutro [Time Frame: weeks 0, 6, 14, 26]; Absolute lymphs [Time Frame: weeks 0, 6, 14, 26]; Absolute mono [Time Frame: weeks 0, 6, 14, 26]; Absolute eos [Time Frame: weeks 0, 6, 14, 26]; Absolute baso [Time Frame: weeks 0, 6, 14, 26]; Immature granulocytes [Time Frame: weeks 0, 6, 14, 26]; Platelets [Time Frame: weeks 0, 6, 14, 26]; PTT [Time Frame: weeks 0, 6, 14, 26]; INR [Time Frame: weeks 0, 6, 14, 26]; SF-36 [Time Frame: weeks 0, 6, 14, 26]; PHQ-9 [Time Frame: weeks 0, 6, 14, 26]
Clinical Trial to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients With Severe Pneumonia Due to COVID-19 (2020)	• Phase I / II Clinical Trial, Multicenter, Randomized and Controlled, Safety and Efficacy study	• 26 participants (Age ≥18, Clinical diagnosis of Pneumonia, severe or critical, caused by COVID-19 infection. Life expectancy > 48 h, Commitment to use a contraceptive method of proven efficacy in both men and women during the duration of the clinical trial.).	•Two doses of 80 million adipose-tissue derived mesenchymal stem cells	No intervention	• Primary outcomes: Safety of the administration of allogeneic mesenchymal stem cells derived from adipose tissue assessed by Adverse Event Rate [Time Frame: 12 months]; Efficacy of the administration of allogeneic mesenchymal stem cells derived from adipose tissue assessed by Survival Rate [Time Frame: 28 days]	Completed
Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19 (2020)	• Phase II Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study	• 53 participants (Men, and women, > 18 years of age inclusively, Patient is hospitalized due to suspected COVID-19 infection, Agrees to the collection of venous blood per protocol).	• 4 IV infusions of HB-adMSCs at 100 million cells/dose. HB-adMSC infusions will occur at day 0, 3, 7, and 10.	• 4 IV infusions of placebo (saline solution). Infusions will occur at day 0, 3, 7, and 10.	• Primary outcomes: IL-6, CRP, Oxygenation, TNF alpha, IL-10 [Time Frame: screening, day 0, 7. 10]; Return to room air (RTRA) [Time Frame: Day 0, 3, 7, 10, 28].	Terminated (No need to continue with vaccine available)
					• Secundary outcomes: EKG qt interval, Leukocyte differential, Glucose, Ca, Albumin, Total protein, Na, Total carbon dioxide, K, Cl, BUN, Cr, AP, ALT, Total BI, White blood cells, Red blood cells, Hb, Ht, MCV, MCHb,MCHbC, Red celldistribution width, Neutro, Lymphs, Mono, Eos, Baso, Absolute neutro, Absolute lymphs, Absolute mono, Absolute eos, Absolute baso, Immature granulocytes, PTT, INR, NK cell surface antigen (CD3-CD54+), clinical lab evaluation of percentage of cells CD3- and CD54+ (%), CD4+/CD8+ ratio Myoglobin, Troponin, Creatinine kinase MB, Serum ferritin [Time Frame: screening, day 0, 7, 10]; Adverse events [Time Frame: screening through day 28]; 7-point ordinal scale [Time Frame: screening, day 0, 3, 7, 10, 28]; d-dimer [Time Frame: screening, day 0, 7, 10]; Chest X-Ray [Time Frame: Day 0, Day 28]; CT scan [Time Frame: Day 0, Day 28]; PCR test for SARS-CoV-2 [Time Frame: day 0, 3, 7, 10]	Terminated (No need to continue with vaccine available)
Study of Intravenous COVI-MSC for Treatment of COVID-19 ‒ Induced Acute Respiratory Distress (2021)	• Phase II, Randomized, parallelly assignmented, quadruple blinded study	• 100 participants (Men, and women, > 18 years Laboratory-confirmed SARS-CoV-2 infection, Hospitalized with COVID-19-induced ARD or ARDS with a PaO2/FiO2 ≤300; Requires oxygen supplementation at Screening; Willing to follow contraception guidelines	• IV infusions of COVI-MSC (two vials or a total of ≈30 million cells) on Day 0, Day 2, and Day 4	• IV infusions of placebo (two vials) on Day 0, Day 2, and Day 4	• Primary outcomes: All-cause mortality rate at Day 28 [Time Frame: Baseline through Day 28];	Recruiting
					• Secundary outcomes: All-cause mortality rate at Day 60 and Day 90 [Time Frame: Baseline through Day 60 and Day 90]; Number of ventilator-free days through Day 28 [Time Frame: Baseline through Day 28]; Number of ICU days through Day 28 [Time Frame: Baseline through Day 28]; Change in clinical status [Time Frame: Baseline to Day 28]; Change in oxygenation [Time Frame: Baseline to Day 2, Day 4, Day 6, Day 14 and Day 28]	Recruiting
Randomized Double-Blind Phase 2 Study of Allogeneic HB-adMSCs for the Treatment of Chronic Post-COVID-19 Syndrome (HBPCOVID02) (2021)	• Phase II, Randomized, Double-blinded, Single-center, Efficacy, and Safety Study	• 80 participants (Men, and women, 18‒70 years, proof of Post COVID-19 Syndrome in their medical records, diagnosed with Chronic post-COVID-19 syndrome for at least twelve weeks before, one or more neurological symptoms, participants should not be pregnant or plan to become pregnant during study participation and six months after the last investigational product administration, If their sexual partners can become pregnant, male participants should use a method of contraception during study participation and for six months after the last administration of the experimental drug, The study participant is able and willing to comply with the requirements of this clinical trial.	• ASCs (Does not describe the dosage)	• Sterile Normal Saline	• Primary outcomes: Changes in Visual Analog Scale of Neurological Symptoms. - Extreme fatigue, Changes in Visual Analog Scale of Neurological Symptoms. ‒ Brain fog, Changes in Visual Analog Scale of Neurological Symptoms. ‒ Headache, Changes in Visual Analog Scale of Neurological Symptoms. ‒ Sleep disturbances, Changes in Visual Analog Scale of Neurological Symptoms. ‒ Loss of taste, Changes in Visual Analog Scale of Neurological Symptoms. ‒ Loss of smell, Incidence of treatment-emergent Adverse Event (TEAEs), Incidence of treatment-emergent Serious Adverse Events (SAEs), AEs of special interest (serious or non-serious) ‒ thromboembolic events, AEs of special interest (serious or non-serious) ‒ thromboembolism of the extremities. [Time Frame: Baseline to Weeks 26]. Incidence and risk of AEs of special interest (serious or non-serious), including peripheral events defined as, thromboembolism of the extremities, AEs of special interest (serious or non-serious) - infections, Incidence and risk of AEs of special interest (serious or non-serious), including infections, AEs of special interest (serious or non-serious) - hypersensitivities, Changes in Laboratory values. - CBC, Changes in Laboratory values. - CMP, Changes in Laboratory values. ‒ Coagulation Panel, Changes in Vital Signs. ‒ Respiratory Rate (breaths per minute), Changes in Vital Signs. ‒ Heart Rate (beats per minute), Changes in Vital Signs. ‒ Body Temperature (Fahrenheit), Changes in Vital Signs. ‒ Blood Pressure (mmHg), Changes in Weight in lb., Changes in Physical examination results. ‒ General [Time Frame: Baseline to Weeks 26], Clinically significant changes in general physical examination results. Changes in Physical examination results. ‒ Body Systems [Time Frame: Baseline to Weeks 26]	Recruiting
			• ASCs (Does not describe the dosage)	• Sterile Normal Saline	• Secundary outcomes: Changes in Subject's energy ‒ Fatigue Assessment form, Changes in Visual Analog Scale of non-Neurological Symptoms. ‒ Dyspnea a rest, Changes in Visual Analog Scale of non ‒ Neurological Symptoms. ‒ Dyspnea with activity, Changes in Visual Analog Scale of non ‒Neurological Symptoms. - Cough, Changes in Visual Analog Scale of non ‒ Neurological Symptoms. ‒ Body aches, Changes in Visual Analog Scale of non-Neurological Symptoms. ‒ Joint pain, Changes in Subject's quality of life ‒ Short Form 36 Health Survey Questionnaire, Changes in Subject's level of depression ‒ PHQ 9 scale. [Time Frame: Baseline to Weeks 26]	Recruiting
BAttLe Against COVID-19 Using Mesenchymal Stromal Cells (2020)	• Phase II Two-treatment,Randomized, Controlled, Multicenter Clinical Trial	• 80 participants (Men,women, 18‒70 years, proof of Post COVID-19 Syndrome, participants should not be pregnant or plan to become pregnant during study participation and six months after the last investigational product administration, If their sexual partners can become pregnant, male participants should use a method of contraception during study participation and for six months after.	• Two serial doses of 1.5 million adipose-tissue derived mesenchymal stem cells per kg	• Regular respiratory distress treatment	• Primary Outcomes: Efficacy of the administration of allogeneic mesenchymal stem cells derived from adipose tissue assessed by Survival Rate) [Time Frame: 28 days]; Safety of the administration of allogeneic mesenchymal stem cells derived from adipose tissue assessed by Adverse Event Rate [Time Frame: 6 months]	Suspended (lack of financial support)
Intermediate Size Expanded Access Protocol for the Treatment of Post-COVID-19 Syndrome (2021)	• Does not describe study method or phase	• Does not describe number os participants	• Route: Intravenous	• Does not describe if there is a control group	• Does not describe the outcomes	No longer available
	• Does not describe study method or phase	• Does not describe number os participants	• Dose: 200 million autologous adipose derived mesenchymal stem cells.	• Does not describe if there is a control group	• Does not describe the outcomes	No longer available
Study to Evaluate the Efficacy and Safety of AstroStem-V in Treatment of COVID-19 Pneumonia (2020)	• Phase I/Ⅱa, open label, single group assignment, Trial to Explore the Safety and Efficacy study	• 10 participants (19‒80 years; diagnosed with pneumonia by radiologic examination, hospitalized for pneumonia caused by COVID-19 infection at screening, subject who has moderate COVID-19 disease, voluntarily participate in the clinical trial with written informed consent	• ASCs (Does not describe the dosage)	None	• Primary outcomes: Treatment related adverse events [Time Frame: From baseline to Week 12]; Number of subjects with treatment related abnormal variation of vital signs, physical examination and laboratory test values [Time Frame: From baseline to Week 12]	Not yet recruiting
			• ASCs (Does not describe the dosage)	None	• Secondary outcomes: Oxygenation index (PaO2/FiO2 ratio) [Time Frame: From baseline to Week 12]; Mortality rate [Time Frame: Week 4, Week 8, and Week 12]; Ventilator treatment status [Time Frame: From Week 1 to Week 12]; Improvement of pneumonia [Time Frame: From baseline to Week 12]; SOFA [Time Frame: From baseline to Week 12]; 2019 nCOV nucleic acid test [Time Frame: From baseline to Week 12].	Not yet recruiting
Cx611-0204 SEPCELL Study (2020)	• Phase Ib/IIa, randomised, double-blind, multicentre trial.	• 84 patients with 18-80 years; body weight 50-100 kg; clinical diagnosis of sCABP (within ≤21 past days) + radiographic findings; ICU management, IMV or treatment with vasopressors for at least 2 h, negative pregnancy treatment.	• Two central line infusions of Cx611 administered within 3 days (on days 1 and 3) at a dose of 160 million cells each	• Will receive SoC therapy according to local guidelines plus two intravenous central line infusions of Ringer Lactate.	• Primary outcomes: safety profile and potential immunological host responses against the administered cells during the follow-up period.	Completed
			• Does not describe stem cell (CD) markers
			•Follow up: up to day 730		• Secondary outcomes: explore the clinical efficacy of Cx611 in terms of a reduction of the duration of mechanical ventilation and/or the need for vasopressors and/or improved survival and/or clinical cure of the sCABP, as well as other efficacy-related endpoints.

vertical_align_top file_download show_chart

more_horizclose
- image
- translate
- link
- article
- vertical_align_top
- file_download
- show_chart
- image
- translate
- link
- article

location_on

Faculdade de Medicina / USP Rua Dr Ovídio Pires de Campos, 225 - 6 and., 05403-010 São Paulo SP - Brazil, Tel.: (55 11) 2661-6235 - São Paulo - SP - Brazil
E-mail: clinics@hc.fm.usp.br

rss_feed Acompanhe os números deste periódico no seu leitor de RSS

Acessibilidade / Reportar erro